por
John R. Fischer, Senior Reporter | October 12, 2021
"Specifically, the new VersaCross platform further streamlines transseptal crossing procedures and therapy delivery by offering the same benefits while eliminating potential wire and sheath exchanges, which may help mitigate risks during procedures," said Boston Scientific. "Bringing the two organizations together also allows for partnership in key development areas."
Baylis Medical Company’s solutions make transseptal access to the left side of the heart more predictable and safe. They also improve the safe and effective transseptal puncture of the left heart during procedures. The Baylis Medical product development activities are expected to continue at the Baylis Medical facilities in collaboration with Boston Scientific's rhythm management and interventional cardiology businesses headquartered in Minnesota. Boston Scientific expects its existing international market reach to open up new opportunities that will help accelerate the adoption of Baylis Medical technologies globally.
"We look forward to making these life-changing technologies available to more patients across the globe through the significant commercial reach of Boston Scientific,” said Kris Shah, president of Baylis Medical Company, in a statement.
Earlier this year, Boston Scientific
acquired Preventice Solutions for $1.2 billion. The deal gave it access to mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors to cardiac event monitors and mobile cardiac telemetry. It also just last month
acquired Devoro Medical, the developer of the WOLF Thrombectomy Platform, which is designed with finger-like prongs to retrieve and remove thrombi in the arterial and venous systems.
The NRG platform was cleared by the FDA in 2008 and has been used in over one million procedures. VersaCross got clearance in 2020.
The deal is expected to be completed in the first quarter of 2022 and is expected to be approximately one cent accretive to adjusted earnings per share in 2022, and increasingly accretive thereafter. It is subject to customary closing conditions.
Back to HCB News
